How Providers Can Support Informed Decision-Making for Patients With Multiple Myeloma

By Cecilia Brown - Last Updated: November 20, 2023

Health care providers should “focus on patient education and ensure adequate time” for informed decision-making in patients with relapsed multiple myeloma, according to a recent study.

Researchers from the HealthTree Foundation for Multiple Myeloma presented the study results during the Academy of Oncology Nurse & Patient Navigators 14th Annual Navigation & Survivorship Conference. The study focused on exploring the role of education and time allocation in decision-making and satisfaction in patients with relapsed or refractory multiple myeloma.

The investigators surveyed patients with multiple myeloma within the HealthTree Cure Hub platform to “gain insights into their decision-making process and satisfaction with treatment decisions, which is crucial for improving care.” The survey included 565 patients with multiple myeloma; the median patient age was 65 years. Of these patients, 253 answered 4 key questions, which the researchers analyzed using linear regression and correlation analysis. The researchers observed relationships between the level of patient education and treatment decisions, time given between treatments, time used for decision-making, and comfort with the final treatment decision.

In patients with relapsed or refractory multiple myeloma, 76% were satisfied or very satisfied with the education level they received, 20% were neither satisfied nor dissatisfied, and 4% were dissatisfied or very dissatisfied. Nearly Reall (91%) of patients with relapsed or refractory disease reported being comfortable or very comfortable with their treatment decision-making, 7% were neither comfortable nor uncomfortable with it, and 2% were uncomfortable or very uncomfortable with it.

The level of education satisfaction had a positive impact on predicting comfort with the final treatment decision (P<.001), and there was a “weak positive association” between comfort with the treatment decision and time allowed for decision-making (P=.002). The researchers also found a “weak negative association” between the time to change therapy and comfort with the final treatment decision (P=.004).

According to the presenters, the study provided “valuable insights” into the decision-making processes of patients with multiple myeloma at the time of their disease relapsing or becoming refractory. The results also “highlight the importance of patient education, with higher levels of education positively influencing comfort with the treatment decisions.”

The researchers concluded that the study’s findings “emphasize the significance of sufficient time allocation for decision-making, as longer intervals are associated with increased comfort,” meaning that providers should “focus on patient education and ensure adequate time for informed decision-making to enhance patient satisfaction with treatment outcomes in [multiple myeloma] at relapse.”

Reference

Calloway-Campbell MG, Flores Perez PA, Jensen R, et al. Exploring patient decision-making and satisfaction in relapsed/refractory multiple myeloma: the role of education and time allocation. Presented at the Academy of Oncology Nurse & Patient Navigators 14th Annual Navigation & Survivorship Conference; November 15-19, 2023; San Antonio, Texas.

Post Tags:AONN 2023 Annual Conference
Advertisement
Advertisement